Inovio Pharmaceuticals, Inc.
INO· Nasdaq
INOInovio Pharmaceuticals, Inc.
Filed Mar 1, 2022 · 10-K · 60 days after period end · 0001055726-22-000008
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $839.12K | $5.58M | $279.49K | $2.50M |
| Net Income | -$106.95M | -$24.34M | -$37.66M | -$32.96M |
| EPS Diluted | — | -$0.14 | -$0.38 | -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 1, 2022 · 60 d after period end
